IGS GeboJagema

IGS GeboJagema, based in the Netherlands, specializes in the design, manufacturing, and maintenance of high-precision molds for critical applications, particularly in the healthcare sector. Founded in 1995 in Eindhoven, Netherlands, IGS GeboJagema focuses on high-precision mold-making. The company has undergone significant developments in its operational strategies over the years, though no specific pivots or changes have been documented. IGS GeboJagema operates independently and does not have known subsidiaries.

Their CEO is Herman Rusch, who has a history in leading companies in the manufacturing sector. The firm has completed a total of 3 deals; the most recent deal was on June 4, 2025. IGS GeboJagema specializes in the design, manufacturing, qualification, and maintenance of high-precision molds essential for critical applications across various industries, particularly in healthcare. The company's core offerings include molds used for medical devices such as glasses, contact lenses, asthma inhalers, insulin pens, and blood diagnostic devices, where precision is paramount.

Their expertise encompasses rigorous testing and validation processes to ensure that their products meet the highest standards of quality and reliability. IGS serves a diverse client base, including manufacturers in Europe, North America, and Asia, who rely on these molds for their advanced medical and industrial applications, enhancing the health and well-being of end-users around the world. In the most recent fiscal year of 2023, IGS GeboJagema reported a revenue of USD 62. 76 mn and an EBITDA of USD 16.

85 mn. The company's revenue structure is primarily derived from B2B partnerships with manufacturers in the healthcare and industrial sectors. They engage in direct transactions for the supply of precision molds, which may include customized design services and ongoing maintenance agreements. While specific pricing details for individual products or services are not disclosed, the focus on high-quality, precision-driven solutions positions their offerings as premium products in the marketplace, fostering long-term relationships with customers.

Looking ahead, IGS GeboJagema plans to enhance its product portfolio and expand its global presence with the assistance of recent funding. The company is set to introduce new products, which are currently in the design phase, to meet the evolving demands of the healthcare industry. They aim to enter new geographic markets, specifically targeting expansion into North America and Asia by the end of 2025. The recent acquisition by BC Partners, which agreed to acquire a majority stake in IGS GeboJagema on June 4, 2025, will support these growth initiatives, allowing the company to accelerate its expansion and continue delivering its solutions effectively.